Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-2232 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: ALN-2232 | EXPERIMENTAL | Participants will be administered a single dose of ALN-2232 |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo |
| Part B: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: ALN-2232 | EXPERIMENTAL | Participants will be administered multiple doses of ALN-2232 |
| Part C: Placebo | PLACEBO_COMPARATOR | Participants will be administered multiple doses of placebo |
| Part C: Tirzepatide | OTHER | Participants will be administered multiple doses of tirzepatide once weekly |
| Name | Type | Description |
|---|---|---|
| ALN-2232 | DRUG | ALN-2232 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Tirzepatide | DRUG | Tirzepatide will be administered SC |
Inclusion Criteria: All Parts: * Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2 * Has a hemoglobin A1c (HbA1c) \<6.5% Exclusion Criteria: All Parts: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise partici...
Top 20 of 32 competitors
ALN-2232 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in participants with obesity to evaluate its safety and efficacy.
ALN-2232 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with obesity.
ALN-2232 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants with obesity to assess the drug's safety, tolerability, and pharmacokinetics.
ALN-2232 is being evaluated in a single Phase 1 clinical trial with the identifier NCT07463846. This randomized, double-blind, placebo-controlled study is recruiting 156 participants with obesity in Canada. The trial is currently active and recruiting, with an enrollment age minimum of 18 years.
Yes, ALN-2232 is a small molecule therapeutic. It is being developed as a metabolic treatment for obesity. The drug is administered in a clinical trial setting and is currently in Phase 1 development, meaning it is still in the early stages of clinical testing.